Absci Corporation - Common Stock (ABSI)

Competitors to Absci Corporation - Common Stock (ABSI)

Amgen Inc. 

Amgen is a biopharmaceutical company that employs advanced biotechnology and research methodologies to develop novel therapies. They compete with Absci Corporation in the domain of biologics and synthetic biology, particularly in cases of drug discovery and development. Amgen has established expertise, a robust product pipeline, and significant resources that allow it to maintain a strong market presence, which may lead them to have a competitive advantage over newer entrants like Absci.

Genentech (Roche Holding AG)

Genentech, a subsidiary of Roche, is a leader in the field of biopharmaceuticals, focusing on cutting-edge research in biologics and monoclonal antibodies. They compete with Absci by leveraging their vast experience and established relationships within the industry to develop and market innovative therapies. Genentech's capital strength and its historically successful launch of numerous blockbuster drugs provide a competitive edge that may position it as a leader in comparison to Absci's more nascent technology offerings.

Sana Biotechnology, Inc. 

Sana Biotechnology focuses on engineered cells to create and deliver new therapies. While both Sana and Absci work within the biopharmaceutical space, Absci's focus on AI-driven protein synthesis and biomanufacturing technologies differentiates its competitive scope. Sana, however, has attracted significant investment and employs a robust cell and gene therapy approach, which could offer them a competitive advantage in the rapidly evolving field of genetic treatments.

Twist Bioscience Corporation 

Twist Bioscience operates in the synthetic biology arena, specializing in DNA synthesis and offering services that complement the research and development capabilities of companies like Absci. Both companies leverage advanced technology to produce biologics, but Twist's established expertise in synthetic DNA sequences gives it a competitive advantage in the customization and scalability of DNA synthesis needed for biologics development, making it a formidable competitor to Absci.